Lomibuvir clinical trials
Also written VX-222.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses lomibuvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lomibuvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionTerminatedPhase 2Vertex Pharmaceuticals IncorporatedNCT01080222Written as VX-222How we know
- A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated CirrhosisCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01516918Written as VX-222How we know
- VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis CCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01581138Written as VX-222How we know
- Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy SubjectsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT00958152Written as VCH-222How we know
Codes
What other systems call lomibuvir · ClinicalTrials.gg INT000109
- MeSH (NLM) C000592793lomibuvirOne source NLM
- UNII (FDA) 37L2LF4A2DLOMIBUVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q27256682lomibuvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166650LomibuvirOne source FDA
- DrugBank DB11954One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592793 | lomibuvir | One source NLM |
| UNII (FDA) | 37L2LF4A2D | LOMIBUVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27256682 | lomibuvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166650 | Lomibuvir | One source FDA |
| DrugBank | DB11954 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.